BAP1 Haploinsufficiency Predicts a Distinct Immunogenic Class of Malignant Peritoneal Mesothelioma
R. Shrestha, N. Nabavi, Y.-Y. Lin, F. Mo, S. Anderson, S. Volik, H. H. Adomat, D. Lin, H. Xue, X. Dong, R. Shukin, R. H. Bell, B. McConeghy, A. Haegert, S. Brahmbhatt, , C. C. Collins
The paper identifies BAP1 loss as a marker for a distinct immunogenic PeM subtype, suggesting potential therapeutic targets like immune checkpoint inhibitors.
bioRxiv · Dec 13, 2018Cancer Biology